JP2021512608A - マクロファージ分極のための方法及び組成物 - Google Patents

マクロファージ分極のための方法及び組成物 Download PDF

Info

Publication number
JP2021512608A
JP2021512608A JP2020542161A JP2020542161A JP2021512608A JP 2021512608 A JP2021512608 A JP 2021512608A JP 2020542161 A JP2020542161 A JP 2020542161A JP 2020542161 A JP2020542161 A JP 2020542161A JP 2021512608 A JP2021512608 A JP 2021512608A
Authority
JP
Japan
Prior art keywords
extracellular vesicle
macrophage
certain embodiments
aso
macrophages
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2020542161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512608A5 (enExample
Inventor
スリラム サティヤナラヤナン，
スリラム サティヤナラヤナン，
ダグラス イー． ウィリアムズ，
ダグラス イー． ウィリアムズ，
ダリア ブジン，
ダリア ブジン，
アダム トーマス ブティン，
アダム トーマス ブティン，
スシュルト カメルカル，
スシュルト カメルカル，
Original Assignee
コディアック バイオサイエンシーズ， インコーポレイテッド
コディアック バイオサイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コディアック バイオサイエンシーズ， インコーポレイテッド, コディアック バイオサイエンシーズ， インコーポレイテッド filed Critical コディアック バイオサイエンシーズ， インコーポレイテッド
Publication of JP2021512608A publication Critical patent/JP2021512608A/ja
Publication of JP2021512608A5 publication Critical patent/JP2021512608A5/ja
Priority to JP2024154757A priority Critical patent/JP2024166292A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020542161A 2018-02-12 2019-02-12 マクロファージ分極のための方法及び組成物 Ceased JP2021512608A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024154757A JP2024166292A (ja) 2018-02-12 2024-09-09 マクロファージ分極のための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862629563P 2018-02-12 2018-02-12
US62/629,563 2018-02-12
PCT/US2019/017731 WO2019157535A1 (en) 2018-02-12 2019-02-12 Methods and compositions for macrophage polarization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024154757A Division JP2024166292A (ja) 2018-02-12 2024-09-09 マクロファージ分極のための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2021512608A true JP2021512608A (ja) 2021-05-20
JP2021512608A5 JP2021512608A5 (enExample) 2022-02-22

Family

ID=65729420

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542161A Ceased JP2021512608A (ja) 2018-02-12 2019-02-12 マクロファージ分極のための方法及び組成物
JP2024154757A Pending JP2024166292A (ja) 2018-02-12 2024-09-09 マクロファージ分極のための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024154757A Pending JP2024166292A (ja) 2018-02-12 2024-09-09 マクロファージ分極のための方法及び組成物

Country Status (17)

Country Link
US (2) US11512315B2 (enExample)
EP (2) EP3752615B1 (enExample)
JP (2) JP2021512608A (enExample)
KR (1) KR20200120624A (enExample)
CN (2) CN119614501A (enExample)
AU (1) AU2019218991A1 (enExample)
BR (1) BR112020016228A2 (enExample)
CA (1) CA3088009A1 (enExample)
CL (1) CL2020002053A1 (enExample)
CO (1) CO2020009694A2 (enExample)
EA (1) EA202091486A1 (enExample)
IL (1) IL276409A (enExample)
MX (1) MX2020008103A (enExample)
PH (1) PH12020551195A1 (enExample)
SG (1) SG11202006021SA (enExample)
TW (1) TW202003846A (enExample)
WO (1) WO2019157535A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019218991A1 (en) 2018-02-12 2020-07-09 Lonza Sales Ag Methods and compositions for macrophage polarization
AU2019242912B2 (en) 2018-03-28 2025-07-17 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in DNA isolated from exosomes
US12312584B2 (en) 2018-10-02 2025-05-27 Exosome Therapeutics, Inc. cGMP exosome loaded therapeutics for treating sickle cell disease
WO2020106772A1 (en) * 2018-11-19 2020-05-28 Exosome Therapeutics, Inc. Exosome loaded therapeutics for the treatment of non-alcoholic steatohepatitis, diabetes mellitus type 1 and type 2, atherosclerotic cardiovascular disease, and alpha 1 antitrypsin deficiency
KR20220078565A (ko) * 2019-08-14 2022-06-10 코디악 바이오사이언시즈, 인크. 분자에 연결된 세포외 소포 및 이의 용도
WO2021030769A1 (en) * 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicles with nras antisense oligonucleotides
JP2022544289A (ja) * 2019-08-14 2022-10-17 コディアック バイオサイエンシーズ， インコーポレイテッド Ｓｔａｔ６を標的とする細胞外小胞－ａｓｏ構築物
CN114641570A (zh) * 2019-08-14 2022-06-17 科迪亚克生物科学公司 具有靶向kras的反义寡核苷酸的细胞外囊泡
BR112022002690A2 (pt) * 2019-08-14 2022-08-23 Codiak Biosciences Inc Construtos de vesícula-aso extracelular tendo como alvo cebp/beta
JP2022549328A (ja) * 2019-09-25 2022-11-24 コディアック バイオサイエンシーズ， インコーポレイテッド 細胞外小胞組成物
CN115297850A (zh) * 2019-12-05 2022-11-04 得克萨斯州大学系统董事会 用于肝纤维化和其他与纤维化相关的疾病的基于外排体的治疗
CN115768877A (zh) 2020-05-11 2023-03-07 斯特姆生物公司 与巨核细胞来源的细胞外囊泡相关的组合物和方法
WO2021237100A1 (en) * 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
CN111748523B (zh) * 2020-07-17 2022-11-22 南通大学 一种免疫调节小胞外囊泡的制备方法及其用途
WO2022076596A1 (en) * 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
US20230405118A1 (en) * 2020-10-30 2023-12-21 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Stat-activated macrophages, compositions, and uses thereof
AU2022216260A1 (en) * 2021-02-03 2023-08-17 Research Institute At Nationwide Children's Hospital Compositions and methods for treating disease associated with dux4 overexpression
US12521449B2 (en) 2021-04-26 2026-01-13 Strm.Bio Incorporated Compositions and methods related to megakaryocyte-derived extracellular vesicles for Fanconi Anemia
CN113262305B (zh) * 2021-05-27 2022-03-25 浙江大学 Coro1a基因作为靶点在制备抗肿瘤药物中的应用
EP4365175A4 (en) 2021-07-02 2025-06-25 Spark Biopharma, Inc. Novel benzopyran derivative and use thereof
CN113521252B (zh) * 2021-07-29 2022-12-20 南开大学 Tnfsf15蛋白作为巨噬细胞免疫增强剂的用途及其活化方法
US20240392293A1 (en) * 2021-09-02 2024-11-28 Molecular Axiom, Llc Compositions and methods for modulating kras expression
CN118434857A (zh) * 2021-10-21 2024-08-02 纳诺瑟拉生物科学股份有限公司 用于沉默kras的组合物以及方法
CN114058621B (zh) * 2021-12-03 2023-06-16 温州医科大学 一种lncRNA基因修饰细胞分泌的外泌体及应用
CN114209814B (zh) * 2021-12-15 2024-02-23 南开大学 Tnfsf15蛋白在促进骨髓干细胞分化为巨噬细胞并扩增中的用途
CN114561347A (zh) * 2022-02-25 2022-05-31 和携科技有限公司 一种脂肪间充质干细胞的培养基和培养方法
CN115948496A (zh) * 2022-04-15 2023-04-11 健艾仕生物医药科技(杭州)有限公司 一种巨噬细胞极化过程高通量检测的方法及应用
CN115137708B (zh) * 2022-06-24 2023-05-16 重庆医科大学 装载yap1核酸序列的肝纤维化靶向纳米颗粒及其制备方法和应用
EP4554984A1 (en) * 2022-07-13 2025-05-21 Navidea Biopharmaceuticals, Inc. Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells
CN115261410A (zh) * 2022-07-20 2022-11-01 中山大学 一种基因编辑工程化m1型巨噬细胞外泌体的制备方法及其应用
EP4599252A2 (en) * 2022-08-26 2025-08-13 Georgia State University Research Foundation, Inc. Treating chronic inflammation and cancer by macrophage polarization
CN115814108B (zh) * 2022-12-27 2025-04-25 华中科技大学 一种用于个性化肿瘤治疗的工程化巨噬细胞载药微颗粒制剂及其制备方法
CN116370647B (zh) * 2023-04-11 2025-07-11 吉林大学 一种用于胰腺癌免疫治疗的工程化外泌体及制备方法
CN119215144B (zh) * 2023-09-08 2025-08-08 首都医科大学附属北京朝阳医院 Lrg1在制备促进巨噬细胞向m1型分化的药物中的应用和巨噬细胞激活剂
KR102635831B1 (ko) * 2023-11-01 2024-02-13 강원대학교 산학협력단 Cxcl11에 의한 m2 대식세포의 재분극 유도를 통한 폐섬유화증 치료 용도

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115634A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals, Inc. Modulation of stat 6 expression
WO2008049424A2 (de) * 2006-10-24 2008-05-02 Halmon Beheer B.V. Pharmazeutische zusammensetzung zur behandlung allergischer erkrankungen
JP2012531888A (ja) * 2009-04-03 2012-12-13 ダイセルナ ファーマシューティカルズ， インコーポレイテッド 非対称二本鎖ｒｎａによる特異的阻害のための、方法および組成物
WO2016201323A1 (en) * 2015-06-10 2016-12-15 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
WO2017053722A1 (en) * 2015-09-24 2017-03-30 Ionis Pharmaceuticals, Inc. Modulators of kras expression
WO2017161010A1 (en) * 2016-03-15 2017-09-21 Codiak Biosciences, Inc. Therapeutic membrane vesicles
JP2017537070A (ja) * 2014-10-24 2017-12-14 アストラゼネカ アクチボラグ 組合せ

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517644B1 (en) * 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
BR0111798A (pt) * 2000-06-19 2006-12-26 Halliburton Energy Serv Inc aparelho e métodos para aplicação de vsp de retardo de tempo para monitorar um reservatório
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
DE102004026309A1 (de) * 2004-05-26 2005-12-29 Haarlems Allergenen Laboratorium B.V. Pharamzeutische Zusammensetzung zur Behandlung allergischer Erkrankungen, pathologischer Atemswegsveränderungen und von Krebs durch Modulation der Genexpression des Stat6
WO2010115202A2 (en) * 2009-04-03 2010-10-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
US20150301058A1 (en) * 2012-11-26 2015-10-22 Caris Science, Inc. Biomarker compositions and methods
US20160243192A1 (en) * 2013-10-17 2016-08-25 Children's Hospital Los Angeles Antibody dependent exosome therapy
US20160346334A1 (en) * 2014-02-05 2016-12-01 Stc.Unm Exosomes as a therapeutic for cancer
GB201516801D0 (en) * 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof
US12622876B2 (en) 2016-08-22 2026-05-12 Lonza Sales Ag Methods of suppressing delivery of exosomes to liver and spleen
MX2020001790A (es) 2017-08-25 2020-07-22 Codiak Biosciences Inc Preparacion de exosomas terapeuticos mediante el uso de proteinas de membrana.
AU2019218991A1 (en) 2018-02-12 2020-07-09 Lonza Sales Ag Methods and compositions for macrophage polarization
KR20220078565A (ko) * 2019-08-14 2022-06-10 코디악 바이오사이언시즈, 인크. 분자에 연결된 세포외 소포 및 이의 용도
US20210322405A1 (en) * 2020-04-15 2021-10-21 Washington University Compositions and methods for treating cancer
JP2025509183A (ja) * 2022-03-04 2025-04-11 アイ－エムエービー バイオファーマ ユーエス リミテッド がんの処置のためのｋｒａｓ阻害剤を含む併用療法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115634A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals, Inc. Modulation of stat 6 expression
WO2008049424A2 (de) * 2006-10-24 2008-05-02 Halmon Beheer B.V. Pharmazeutische zusammensetzung zur behandlung allergischer erkrankungen
JP2012531888A (ja) * 2009-04-03 2012-12-13 ダイセルナ ファーマシューティカルズ， インコーポレイテッド 非対称二本鎖ｒｎａによる特異的阻害のための、方法および組成物
JP2017537070A (ja) * 2014-10-24 2017-12-14 アストラゼネカ アクチボラグ 組合せ
WO2016201323A1 (en) * 2015-06-10 2016-12-15 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
WO2017053722A1 (en) * 2015-09-24 2017-03-30 Ionis Pharmaceuticals, Inc. Modulators of kras expression
WO2017161010A1 (en) * 2016-03-15 2017-09-21 Codiak Biosciences, Inc. Therapeutic membrane vesicles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"K-Ras-dependent signalling modulates the activation of infiltrating macrophages associated with a di", PANCREATOLOGY, vol. Volume 13, Issue 3, Supplement, JPN6023041081, 2013, pages 24 - 25, ISSN: 0005341995 *
FASEB JOURNAL, vol. 32, JPN6023007129, January 2018 (2018-01-01), pages 969 - 978, ISSN: 0005341994 *

Also Published As

Publication number Publication date
WO2019157535A1 (en) 2019-08-15
CL2020002053A1 (es) 2020-12-18
PH12020551195A1 (en) 2021-08-16
TW202003846A (zh) 2020-01-16
US12570978B2 (en) 2026-03-10
EP4663245A3 (en) 2026-04-29
CN119614501A (zh) 2025-03-14
CN111918967A (zh) 2020-11-10
EA202091486A1 (ru) 2021-02-08
BR112020016228A2 (pt) 2020-12-08
JP2024166292A (ja) 2024-11-28
MX2020008103A (es) 2020-09-25
US11512315B2 (en) 2022-11-29
AU2019218991A1 (en) 2020-07-09
CO2020009694A2 (es) 2020-10-30
KR20200120624A (ko) 2020-10-21
SG11202006021SA (en) 2020-08-28
EP3752615B1 (en) 2025-08-27
US20200407725A1 (en) 2020-12-31
CA3088009A1 (en) 2019-08-15
US20230365971A1 (en) 2023-11-16
EP4663245A2 (en) 2025-12-17
EP3752615A1 (en) 2020-12-23
CN111918967B (zh) 2024-11-19
EP3752615C0 (en) 2025-08-27
IL276409A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
JP2024166292A (ja) マクロファージ分極のための方法及び組成物
JP7507090B2 (ja) 免疫腫瘍及び抗炎症療法のためのエクソソーム
Qiu et al. Tumor-derived nanovesicles promote lung distribution of the therapeutic nanovector through repression of Kupffer cell-mediated phagocytosis
US20230181758A1 (en) Extracellular vesicles targeting dendritic cells and uses thereof
EP3411063B1 (en) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
CN115998757A (zh) 包含具有双链多核糖核苷酸和聚乙烯亚胺的复合物的粒子的新型药物组合物
JP2022519275A (ja) エクソソーム操作のための膜タンパク質足場
EP4106730A1 (en) Multilamellar rna nanoparticles and methods of sensitizing tumors to treatment with immune checkpoint inhibitors
JP2023538077A (ja) がんの治療方法
EP3917541A1 (en) Combinations, nanoparticles and methods for controlling natural killer cell activation and function
AU2023225704A1 (en) Compositions and methods for modulating the immune system
US20260028632A1 (en) Nucleic acid agents modulating fas isoforms
WO2024256635A1 (en) Dpm1 inhibitor for treating cancer
WO2025134119A1 (en) Reprogrammed dysfunctional natural killer cells and uses thereof
EA045701B1 (ru) Каркасы мембранных белков для конструирования экзосом
HK40043611B (en) Methods and compositions for macrophage polarization
HK40043611A (en) Methods and compositions for macrophage polarization

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240306

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241115

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250108

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20250522